DISSECTING AND EXPLOITING MOLECULAR RECOGNITION AT PROTEIN-PROTEIN INTERFACES

Lead Research Organisation: University of Cambridge
Department Name: Chemistry

Abstract

Proteins regulate many of the processes that are crucial for the activity of a living cell. In order to successfully carry out their biological function, proteins often interact in complex with other proteins. The principal subject of the proposed research concerns the development of new approaches to advance our understanding of protein-protein interactions and of how we could disrupt these interactions using the binding of a small molecule. In this project, I focus on studying the binding of small molecules to protein interfaces. I pose the following questions: what features of protein interfaces determine binding and activity (or lack thereof) of a small molecule? Can we modify protein interfaces so that a small molecule can 'stick' to the surface better and better? What can we learn from these new interfaces? How can we use such information to discover new compounds that could function in the cell by binding tightly to these sites? To interrogate protein interfaces, I will first use protein engineering, a technique to generate mutations on a protein by changing amino acids, the building blocks of proteins, from one type to another. I will make mutations in a defined manner, by replacing large amino acids at the protein interface with smaller and smaller ones, hence creating larger and larger cavities. The location and strength of small molecules bound to these engineered pockets will be determined. This will provide useful information to find other protein interfaces that may be functional in living organisms, and that may have the potential to be disrupted using small molecules. Secondly, I will exploit this knowledge further to facilitate identification of small molecules that function by disrupting a protein interface. I will develop new methods to detect small molecules that bind together to adjacent sites of the interface. For this purpose, I will use nuclear magnetic resonance (NMR) spectroscopy, a technique that allows monitoring the hydrogen atoms of small molecules and that can report if these are bound to a protein close to one another. I will also make crystals of the protein in which the interface is accessible to small molecules, and let these molecules react together as they are bound close to each other at the protein surface. Since the structure of a small molecule bound to the protein can be determined directly by shooting X-ray radiations at the protein crystal, a technique called X-ray crystallography, this is a rapid way of identifying any compound that has successfully assembled at the protein interface. The research is important and exciting for the following reasons: 1. Protein interfaces tend to be relatively flat and featureless, as they were not 'evolved' by nature to bind small molecules. The modulation of protein-protein interactions using small molecules is therefore a challenging task, and is at the forefront of molecular recognition. 2. A new scientific horizon is to advance our understanding of biological systems by disrupting pathways and networks in a selective fashion inside the cell. As protein-protein interactions occur widely within the cell, their modulation using small molecules offers an opportunity to interrogate and discover new biology. 3. The disruption of protein-protein complexes offers a novel and general mechanism to develop new medicines. In conclusion, this research has the potential to significantly impact on the way new biology and new drugs will be discovered in the future, with wider benefits to society and exciting opportunities in the fight against disease.

Technical Summary

The overall objective of this fellowship application is to advance our fundamental understanding of molecular recognition at protein interfaces by small organic compounds. The project will employ a unique combination of molecular biology and biophysical studies of protein-ligand interactions to dissect the nature of non-covalent interactions at protein interfaces, and to exploit such knowledge with the goal of aiding small molecule design. I will study the interaction of small peptides and fragment-like compounds (MW < 300 Da) to the tumour suppressor Von Hippel-Lindau (pVHL), a protein which is part of a complex responsible for the degradation of the Hypoxia-Inducible Factor (HIF-1) inside the cell. I will use protein engineering to make larger and larger cavities at the pVHL:HIF-1 interface with the aim to bind small molecule with increasingly higher affinities. I will study the fundamental changes to the recognition of the small molecules in terms of structure (using X-ray crystallography) and thermodynamics (using low c value isothermal titration calorimetry). This information will provide a platform for future studies in the following two directions: 1) to find structurally similar protein interfaces that may be druggable, using computational tools and structural databases; 2) to facilitate discovery of novel small molecules that bind with high affinity and specificity to a protein interface, using intermolecular Nuclear Overhauser Effect to identify fragments binding at adjacent sites by NMR spectroscopy, and Dynamic Combinatorial X-ray Crystallography to assemble fragments together in the presence of a protein crystal, with the aim of selecting the highest affinity compound. Together these studies will provide significant new insights into the principles that govern the modulation of protein-protein interactions using small molecules, and new tools for studying systems of biological importance and therapeutic potential.

Publications

10 25 50

publication icon
Alessio Ciulli (Author) (2014) A novel approach to engineer selectivity of bromodomain chemical probes in ChemMedChem

publication icon
Buckley DL (2012) Small-molecule inhibitors of the interaction between the E3 ligase VHL and HIF1a. in Angewandte Chemie (International ed. in English)

 
Description 1) VHL-HIF inhibitors. In collaboration with Craig Crews (Yale University), we have discovered first-in-class small molecules that bind the E3 CRL component von-Hippel Lindau protein (VHL) and disrupt its interaction with substrate Hypoxia Inducible Factor alpha subunit (HIFa) (Van Molle et al., Chem. Biol., 2012; Buckley et al., J. Am. Chem. Soc. 2012; Angew. Chem. Int. Ed. 2012). More recently, my laboratory conducted extensive rational design, guided by liganded crystal structures and biophysical binding characterization, to improve the binding affinity and physicochemical properties of the compounds (Galdeano et al., J. Med. Chem 2014). These exciting discoveries and the resulting filed patents have led to the establishment of spin-off company Arvinas in the U.S. and of a Discovery Platform Unit (DPU) in Protein Degradation within GSK. In 2016, we developed and characterized potent and selective VHL as novel chemical probes of the hypoxic signalling pathway has been accepted for publication in Nature Communication. In brief, chemical strategies to using small molecules to stimulate hypoxia inducible factors (HIFs) activity and trigger a hypoxic response under normoxic conditions, such as iron chelators and inhibitors of prolyl hydroxylase domain (PHD) enzymes, have broad-spectrum activities and off-target effects. In our article, we report VH298, a potent VHL inhibitor that stabilizes HIF alpha and elicits a hypoxic response via a different mechanism, that is blockade of the VHL:HIF ?lpha protein-protein interaction downstream of HIF alpha hydroxylation by PHD enzymes. We show that VH298 engages with high affinity and specificity with VHL as its only major cellular target, leading to selective on-target accumulation of hydroxylated HIF-alpha in a concentration- and time-dependent fashion in different cell lines, with subsequent upregulation of HIF-target genes at both mRNA and protein levels. VH298 represents a high-quality chemical probe of the HIF signaling cascade and an attractive starting point to the development of potential new therapeutics targeting hypoxia signaling. This work is the result of collaboration between my lab and Sonia Rocha (GRE), Doreen Cantrell (CSI) and Kevin Read (DDU) within Dundee SLS. As a result, VH298 is now available to the wide scientific community, and will prove an attractive lead compound for further drug development. The entire structure-activity relationship that led to the identification of VH298 was disclosed later in 2017 in J Med Chem.

2) PROTACs. We have designed molecules based on the discovered VHL ligands, to induce intracellular removal of proteins of interest via the ubiquitin-proteasome system by hijacking and directing proteins to VHL. Such chimaeric molecules (PROTACs) act as chemical degraders of the target as opposed to just inhibitors and more closely phenocopy traditional gene knockdown tools e.g. RNAi. We have recently shown that a compound linking the pan-selective bromo and extraterminal (BET) bromodomain inhibitor JQ1 to our VHL ligand not only induces potent dose- and time-dependent destruction of BET proteins, but crucially is selective for Brd4 over other BET members Brd2 and Brd3, leading to a more limited Brd4-specific transcriptional response when compared to that of pan-inhibitor JQ1 (Zengerle et al., ACS Chem. Biol. 2015). This now provides unprecedented opportunities to study the physiological and therapeutic consequences of intra-BET selective modulation of the drug target Brd4. Two highlights from the Lab published in 2017 have been the first ternary PROTAC crystal structure (published in Nature Chemical Biology) and the first homo-PROTAC inducing an E3 ligase to degrade itself (published n Nature Communications). Our pioneering discoveries in VHL inhibitors and PROTACs have helped to lay the foundation of a new exciting major collaborative agreement with Boehringer Ingelheim on PROTACs, and a recent revolution in approaching targeted protein degradation for drug discovery.

2) Ligandability of CRLs. Using the VHL-HIFa inhibitors as a starting point, we have carried out fundamental analyses of what type of ligands can more effectively probe PPIs and what approaches can best find these molecules (Van Molle et al., Chem. Biol., 2012; Dias et al., ACS Med. Chem Lett., 2014). This research is increasing our understanding of the druggability of PPIs, which helps to intervene effectively and reduce risks associated with tackling such challenging targets.

3) CRL complexes. Using a hybrid approach combining biophysical and structural techniques in innovative ways, and in collaboration with experts in ion-mobility native mass spectrometry (Dr. Djana Matak-Vinkovic, Cambridge and Prof Frank Sobott, Antwerp) and chemoproteomics (Dr Paola Grandi, GSK-Cellzome), we have dissected in increasing level of detail the molecular structure, assembly and interactions of components of complexes and their PTMs within the CRL5-ASB9 (Thomas et al., Biochemistry, 2013) and CRL5-SOCS2 (Bulatov et al., J. Biol. Chem., 2015; Gadd et al., Plos One, 2015).
Exploitation Route by exploiting their potential as chemical tools and therapeutics
Sectors Healthcare,Pharmaceuticals and Medical Biotechnology

URL http://www.lifesci.dundee.ac.uk/groups/alessio-ciulli
 
Description The breakthrough discoveries made by our laboratory and collaborators of potent VHL ligands have led not only to several publications, but also two patents (US 2014356322 and WO 2013106646), and to the establishment of Yale spin-off Arvinas in the US and a Discovery Platform Unit (DPU) within GlaxoSmithKline Stevenage, UK. Such activity represents tangible output of Dr. Ciulli's research in terms of impact, innovation and commercial exploitation. Arvinas and the GSK DPU are pharmaceutical companies both focused on developing small molecule strategies aimed at degrading disease- causing cellular proteins, with a focus in oncology amongst other therapeutic areas.
First Year Of Impact 2012
Sector Healthcare,Pharmaceuticals and Medical Biotechnology
Impact Types Economic

 
Description BBSRC Doctoral Training Account PhD Studentship
Amount £66,000 (GBP)
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 10/2010 
End 09/2014
 
Description BBSRC Responsive Mode grant: A systems approach for the fragment-based development of selective chemical probes of bromodomain function
Amount £578,328 (GBP)
Funding ID BB/J001201/1 
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 11/2011 
End 05/2015
 
Description EPSRC Doctoral Training Account PhD Studentship
Amount £66,000 (GBP)
Funding ID awarded, however student did not move from Cambridge to Dundee so funding reallocated to a different PI 
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Public
Country United Kingdom
Start 10/2012 
 
Description EPSRC Doctoral Training Account PhD Studentship
Amount £66,000 (GBP)
Funding ID fees-only, awarded but withdrawn because other full-cost funding was found 
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Public
Country United Kingdom
Start 10/2011 
 
Description ERC Starting Grant: DrugE3CRL
Amount € 1,500,000 (EUR)
Funding ID ERC Starting Grant 311460 DrugE3CRLs 
Organisation European Research Council (ERC) 
Sector Public
Country Belgium
Start 05/2013 
End 04/2018
 
Description GSK grant: Structure Guided Structure Activity Relationship for VHL Binder Based Protacs
Amount £50,000 (GBP)
Funding ID RG Number: 67080; UFS Project: MAAG/937 
Organisation GlaxoSmithKline (GSK) 
Sector Private
Country Global
Start 04/2012 
End 08/2012
 
Description MIUR Messaggeri della Conoscenza - Drug Discovery
Amount € 40,000 (EUR)
Funding ID ID 497 - Drug Discovery 
Organisation Italian Ministry of Education, Universities and Research 
Sector Public
Country Italy
Start 07/2013 
End 11/2014
 
Description Marie Curie Intra-European Fellowships for Career Development (IEF)
Amount £169,110 (GBP)
Funding ID FP7-PEOPLE-2010-IEF-275683 pVHL-CRL 
Organisation European Commission 
Sector Public
Country European Union (EU)
Start 03/2011 
End 02/2013
 
Description Marie Curie Intra-European Fellowships for Career Development (IEF)
Amount € 200,000 (EUR)
Funding ID EU FP7-PEOPLE-2012-IEF 328030 orthoPROTACS 
Organisation European Commission 
Sector Public
Country European Union (EU)
Start 04/2013 
End 04/2015
 
Description Portuguese FCT Studentship
Amount £107,977 (GBP)
Funding ID SFRH/BD/81735/2011 
Organisation Government of the Portugese Republic 
Department Foundation of Science and Technology (FCT)
Sector Public
Country Portugal
Start 01/2012 
End 12/2015
 
Description Application of fragment-based screening towards development of selective inhibitors of protein N-glycosylation pathways in pathogenic gram-negative bacteria 
Organisation Massachusetts Institute of Technology
Country United States 
Sector Academic/University 
PI Contribution This collaboration expands the range of protein binding-site targets for druggability studies. Our preliminary results have identified fragments targeting sugar binding sites, traditionally considered poorly tractable with small molecules, an adjacent site where cofactor CoA binds, as well as an inter-subunit interface of the homo-trimeric bacterial enzyme. These provide exciting opportunities to further develop some of the concepts and hypothesis that are central to my Fellowship proposal. My work on fragment screening and computational design complements nicely with the expertise of the Imperiali lab and efforts on synthetic chemistry, enzyme inhibition and structural studies ongoing in her lab
Collaborator Contribution Led small molecule inhibitor design efforts that initiate as the results of our biophysical fragment screening results
Impact Postdoctoral report, James P. Morrison (MIT) PhD thesis, Michael Morrison (MIT)
Start Year 2009
 
Description BioNMR collaborative project 261863 proposal no. BIO-NMR-00211 entitled: Structural modelling and dynamics of the Bromodomain Adjacent to Zinc finger domain containing protein 2B bromodomain 
Organisation Utrecht University
Country Netherlands 
Sector Academic/University 
PI Contribution Purified proteins to be used in NMR spectroscopic studies and binding assyas, and provided intellectual input
Collaborator Contribution Provided access to NMR facility and provided intellectual input and expertise
Impact 13. Ferguson, F.M., Dias, D.M., Rodrigues, J.P.G.L.M., Wienk, H., Boelens, R., Bonvin, A.M.J.J., Abell, C., Ciulli, A.* Binding hotspots of BAZ2B bromodomain: histone interaction revealed by solution NMR driven docking. Biochemistry, 2014, 53(42), 6706-6716.
Start Year 2013
 
Description BioNMR collaborative project BIO-NMR-00169 entitled: Targeting and characterising multi-protein complexes in Fragment-based drug discovery. Small molecules binding to VHL E3 Ubiquitin Ligase and protein binding partners studied by NMR spectroscopy. 
Organisation Utrecht University
Country Netherlands 
Sector Academic/University 
PI Contribution purified protein samples for NMR spectroscopic studies and provided intellectual input
Collaborator Contribution provide access to NMR instrumentation and facilities and provided intellectual input
Impact multi-disciplinary collaboration, involving NMR spectroscopy, biophysics, protein purification and characterization and drug discovery. Dias, D.M., Ciulli, A.* NMR approaches in structure-based lead discovery: Recent developments and new frontiers for targeting multi-protein complexes. Prog Biophys Mol Biol, 2014, 116(2-3), 101-112
Start Year 2013
 
Description Chemoproteomics of native protein complexes 
Organisation GlaxoSmithKline (GSK)
Department Cellzome Ltd
Country Germany 
Sector Private 
PI Contribution We provided Cellzome with compounds to be used in chemoproteomics studies to recruit native E3 Ubiquitin ligase protein complexes
Collaborator Contribution They performed chemoprotemics studies with our compounds, involving pull-down assays from cell lysates and mass spectrometric measurements to assess composition of recruited proteins and binding affinities of compounds
Impact Bulatov, E., Martin, E.M., Chatterjee, S., Knebel, A., Shimamura, S., Konijnenberg, A., Johnson, C., Zinn, N., Grandi, P., Sobott, F., Ciulli, A.* Biophysical studies on interactions and assembly of full-size E3 ubiquitin ligase: suppressor of cytokine signaling 2 (SOCS2):ElonginBC:Cullin5:RING-box protein 2 (Rbx2). J. Biol. Chem. 2015, 290(7), 4178-4198. Galdeano, Julianty et al. under revision
Start Year 2011
 
Description Development of drug-like small molecule ligands targeting human pVHL protein: towards the next-generation of PROTAC molecules for targeted protein degradation 
Organisation Yale University
Country United States 
Sector Academic/University 
PI Contribution this collaboration aims to discover novel small molecule ligands that target human pVHL, thus it is highly synergistic with the Fellowship proposed research on druggability of pVHL. As the lab focuses efforts on synthetic chemistry and biochemical and cellular assays in vitro and in vivo, it is also highly complementary to my efforts in structural and biophysical studies of protein-ligand interactions
Collaborator Contribution Synthesized and tested over 100 compounds that were informed by our crystallographic structural and biophysical binding studies and fragment-based approaches
Impact 1) Buckley, D.L., Gustafson, J.L., Van Molle, I., Roth, A.G., Tae, H.S., Gareiss, P.C., Jorgensen, W.L., Ciulli, A., Crews, C.M. Small Molecules Inhibitors of the Interaction Between the E3 Ligase VHL and HIF1a. Angew. Chem. Int. Ed., 2012, 51, 11463-11467 2) Van Molle, I., Thomann, A., Buckley, D.L., So, E.C., Lang, S., Crews, C.M., Ciulli, A.* Dissecting fragment-based lead discovery at the von Hippel-Lindau protein:Hypoxia Inducible Factor 1a protein-protein interface. Chem. Biol., 2012, 19, 1300-1312 3) Buckley, D.L., Van Molle, I., Gareiss, P.C., Tae, H.S., Michel, J., Noblin, D.J., Jorgensen, W.L., Ciulli, A.*, Crews, C.M. Targeting the von Hippel-Lindau E3 ubiquitin ligase using small molecules to disrupt the VHL/HIF-1a interaction. J. Am. Chem. Soc., 2012, 134, 4465-4468 4) PhD thesis, Dennis Buckley (Yale University) 5) Patent: Compounds and Methods for the Inhibition of VCB E3 Ubiquitin Ligase United States Provisional Patent Application No. 61/585,736 (Filing Date: 12 Jan 2012) PCT/US2013/021136 (filing date January 11, 2013) WO 2013/106646 (International publication date July 18, 2013) 6) Patent: Compounds and Methods for the Enhanced Degradation of Targeted Proteins and Other Polypeptides by an E3 Ubiquitin Ligase United States Provisional Patent Application No. 61/585,769 (Filing Date: 12 Jan 2012) PCT/US2013/021141 (filing date January 11, 2013) WO 2013/106643 (International publication date July 18, 2013) 7) Spin-out company Arvinas, Yale University (founder: Prof. Craig Crews)
Start Year 2010
 
Description Development of selective chemical tools to interrogate protein-protein interactions involved in the epigenetic regulation of gene transcription 
Organisation University of Oxford
Department Structural Genomics Consortium (SGC)
Country United Kingdom 
Sector Public 
PI Contribution This collaboration has been concentrated initially on the human bromodomains, protein domains that recognize acetylated lysine residues on histone proteins. This project is directly relevant to the Fellowship since it is an example, like pVHL-HIF, of a protein-protein interaction where molecular recognition appears to be dictated by a key post-translational modification of one of the two partner proteins
Collaborator Contribution Provided reagents and material, access to instrumentation, and intellectual input Solved a number of crystal structures Hosted team members for short visits
Impact 1) PhD thesis, Fleur M. Ferguson (University of Cambridge) 2) 10. Tallant, C., Valentini, E., Fedorov, O., Overvoorde, L., Ferguson, F.M., Filippakopoulos, P., Svergun, D., Knapp, S., Ciulli, A.* Molecular basis of histone tail recognition by human TIP5 PHD finger and Bromodomain of the chromatin remodelling complex NoRC. Structure, 2015, 23(1), 80-92. 3) Ferguson, F.M., Fedorov, O., Chaikuad, A., Philpott, M., Muniz, J., Felletar, I., von Delft, F., Heightman, T.D., Knapp, S., Abell, C., Ciulli, A.* Targeting Low-Druggability Bromodomains: Fragment Based Screening and Inhibitor Design Against the BAZ2B Bromodomain. J. Med. Chem., 2013, 56(24), 10183-10187 4) Philpott, M., Yang, J., Tumber, T., Fedorov, O., Uttarkar, S., Filippakopoulos, P., Picaud, S., Keates, T., Felletar, I., Ciulli, A., Knapp, S., Heightman, T.D. Bromodomain-peptide displacement assays for interactome mapping and inhibitor discovery. Mol. Biosyst., 2011, 7, 2899-2908
Start Year 2010
 
Description Ion mobility mass spectrometry to interrogate the structure and assembly of multisubunit protein complexes 
Organisation University of Antwerp
Department Department of Chemistry
Country Belgium 
Sector Academic/University 
PI Contribution We expressed and purified component subunits of the SOCS2-CRL E3 ligases assembled into specific complexes and provided the samples to the collaborator (Prof. Frank Sobott research team)
Collaborator Contribution They performed native nanoelectrospray ionization mass spectrometry and traveling wave ion mobility MS experiments on our samples and analyzed data.
Impact Bulatov, E., Martin, E.M., Chatterjee, S., Knebel, A., Shimamura, S., Konijnenberg, A., Johnson, C., Zinn, N., Grandi, P., Sobott, F., Ciulli, A.* Biophysical studies on interactions and assembly of full-size E3 ubiquitin ligase: suppressor of cytokine signaling 2 (SOCS2):ElonginBC:Cullin5:RING-box protein 2 (Rbx2). J. Biol. Chem. 2015, 290(7), 4178-4198.
Start Year 2014
 
Description Structure Guided Structure Activity Relationship for VHL Binder Based Protacs 
Organisation GlaxoSmithKline (GSK)
Country Global 
Sector Private 
PI Contribution this collaboration aims to discover novel small molecule ligands that induce the degradation of any target protein by recruiting the human VHL E3 ubiquitin ligase. My research team solved >20 crystal structures with small molecules synthesized or identified by GSK researchers bound and provided intellectual input and shared materials and expertise.
Collaborator Contribution Synthesized several compounds informed by the structural information elucidated by my laboratory using X-ray crystallography. Provided material and intellectual input.
Impact 1) Establishment of a Protein Degradation DPU within GSK in January 2013 2) Patent: Compounds and Methods for the Inhibition of VCB E3 Ubiquitin Ligase United States Provisional Patent Application No. 61/585,736 (Filing Date: 12 Jan 2012) PCT/US2013/021136 (filing date January 11, 2013) WO 2013/106646 (International publication date July 18, 2013) 3) Patent: Compounds and Methods for the Enhanced Degradation of Targeted Proteins and Other Polypeptides by an E3 Ubiquitin Ligase United States Provisional Patent Application No. 61/585,769 (Filing Date: 12 Jan 2012) PCT/US2013/021141 (filing date January 11, 2013) WO 2013/106643 (International publication date July 18, 2013)
Start Year 2012
 
Title COMPOUNDS & METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS & OTHER POLYPEPTIDES BY AN E3 UBIQUITIN LIGASE 
Description The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to the ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of targeted polypeptides. 
IP Reference WO2013106643 
Protection Patent application published
Year Protection Granted 2013
Licensed Yes
Impact 1) Spin-out company Arvinas, Yale University (founder: Prof. Craig Crews) 2) Establishment of a Protein Degradation Discovery Platform Unit (DPU) within GSK
 
Title COMPOUNDS AND METHODS FOR THE INHIBITION OF VCB E3 UBIQUITIN LIGASE 
Description The present invention relates to novel compounds which find utility as modulators, especially inhibitors of VCB E3 Ubiquitin Ligase and as bioactive agents for use as therapeutics for the stimulation of erythropoiesis in a patient or subject including inducement of EPO production in the patient or subject, for the treatment of chronic anemia and ischemia (limits brain injury during episodes of localized anemia, ischemia and/or stroke and damage to cardiovascular tissue during cardiovascular ischemia), as well as enhancing wound healing processes. Pharmaceutical compositions comprising effective amounts of compounds according to the present invention alone or in combination with an additional erythropoieses stimulating agent such as EPO under the tradename procrit or epogen or darbapoietin alfa under the tradename aranesp. Methods of stimulating erythropoiesis in a subject or patient, including increasing the number of red blood cells and/or hematocrit of the patient, treating anemia, including chronic anemia and anemia associated with chronic kidney disease, dialysis, and cancer chemotherapy, ischemia, stroke and damage to cardiovascular tissue during cardiovascular ischemia as well as enhancing wound healing processes and preventing/reducing scarring secondary to healing represent additional aspects of the present invention. Local enhancement of angiogenesis through induction of VEGF including wound healing and reduction of stent occlusion remain additional aspects of the present invention. 
IP Reference WO2013106646 
Protection Patent application published
Year Protection Granted 2013
Licensed Yes
Impact 1) Spin-out company Arvinas, Yale University (founder: Prof. Craig Crews) 2) Establishment of a Protein Degradation Discovery Platform Unit (DPU) within GSK
 
Description Alessio delivers the course Drug Discovery to the Dept. of Pharmaceutical Chemistry at the University of Messina, under the realm of the new MIUR-funded programme Messaggeri della Conoscenza 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Participants in your research and patient groups
Results and Impact Taught a course in Drug Discovery which sparked questions, discussions and further interaction. Hosted 4 selected students in my laboratory the following year, and disseminated all activities, also in the form of a video publicly accessible online

Students, teachers and public in Italy more aware of the important of exchange programmes between Italy and UK
Year(s) Of Engagement Activity 2013
URL http://www.youtube.com/watch?v=GxrQwJO9HB8
 
Description Media press release: Bump-and-hole approach brings protein breakthrough 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Media (as a channel to the public)
Results and Impact Media press release covering my laboratory recent article published in Science

After this press release, I have received a notable number of emails from other colleagues and friends to congratulate us with our achievement but also to tell me that they read the press release and this stimulated their interest in learning more about the topic of epigenetics and small molecule chemical biology and drug discovery. Many individuals have already contacted me to make requests for reagents, and many companies interested in this area have also approached me to express their willingness and interest to collaborate with us.

see:
http://www.bbsrc.ac.uk/news/health/2014/141020-pr-bump-and-hole-brings-protein-breakthrough.aspx
http://www.lifesci.dundee.ac.uk/news/2014/oct/22/ciulli-labs-bump-and-hole-approach-leads-protein-breakthrough
Year(s) Of Engagement Activity 2014
URL http://www.bbsrc.ac.uk/news/health/2014/141020-pr-bump-and-hole-brings-protein-breakthrough.aspx